Goldline Pharmaceutical IPO
Market Sentiment
IPO Details
IPO Reservation
Market Lot Size
Financial Analysis
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 19.85 | 23.57 | 28.06 |
| Expense | 19.45 | 21.04 | 24.20 |
| Profit (PAT) | 0.26 | 1.81 | 2.83 |
| Total Assets | 19.39 | 22.93 | 26.28 |
| Company | P/E | EPS | Market Cap (Cr) |
|---|---|---|---|
| Mono Pharmacare Limited | 12.57 | 1.75 | 10 |
| Chandra Bhagat Pharma Limited | 37.73 | 1.14 | 3 |
Promoters: Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
Strengths & Risks
- Heavily oversubscribed — 781.6x overall (so far).
- Strong institutional (QIB) demand — 180.2x.
- Revenue grew 19% in the latest reported year.
- Solid profit margin — 10.1%.
- Strong return on equity — 36%.
- Elevated leverage — debt/equity of 1.50.
Auto-generated from live GMP, subscription, valuation and financial data. Informational only — not investment advice. Always read the RHP before applying.
Company Information
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1. Goldline Pharma, which includes specialities like Physicians, Orthopedics, ENT, Chest Physicians, General and Speciality Surgery, Gastroenterology, Neurology, and Urology, 2. Goldline Cardinal, which includes specialities like Physicians, Diabetologists, Endocrinologists, Cardiologists, and General Physicians, 3. Goldline Ayushman, which includes Pediatricians, Child Specialists, Neonatologists, and General Practitioners, 4. Goldline InLife, which includes Intensivists, Critical Care Consultants, Super Specialty Surgeons, and Physicians, and 5. Goldline Wellness, which includes cancer therapy. The company sells its products across various states, including Maharashtra, Madhya Pradesh, Odisha, Jharkhand, Tamil Nadu, Rajasthan, and Bihar. Moreover, all the products of the firm are sold and distributed under the brand Goldline.
| Purpose | Amount (Cr) |
|---|---|
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | 8.90 |
| General Corporate Purpose | - |
Resources & Documents
Goldline Pharmaceutical Ltd., 103, F-1, Leela Apartment, Shilpa HSG Society,, Near Saptagiri Nagar, Shanidham,, Narendra Nagar,, Nagpur, Maharashtra, 440015
Goldline Pharmaceutical has set a price band of Rs 41–Rs 43 per share for an issue size of Rs 12 crore. The stock listed with a 38.95% gain versus its issue price on May 19, 2026.
Goldline Pharmaceuticals is one of the leading companies involved in the marketing of pharmaceutical products under the name Goldline. Its products are divided into 5 segments: 1.
The issue is promoted by Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal with Cumulative Capital Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company (Rs 9 crore) and General Corporate Purpose.
Grey market is quoting a premium of +Rs 15 (+34.9% over issue price), up Rs 9 from the previous session. Final subscription data records overall subscription at 781.63x, retail at 880.68x, QIB at 180.22x, NII at 1,227.87x.
On fundamentals, the company is posting revenue growth of 19.1%, a profit margin of 10.1%, return on equity of 35.8% in its most recent reported period. Listed peers in this segment include Mono Pharmacare Limited (P/E 12.57x, market cap Rs 10 crore) and Chandra Bhagat Pharma Limited (P/E 37.73x, market cap Rs 3 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector are trading.
Our data-driven engine currently flags this issue as a Strong Subscribe — the data suggests strong listing-day potential backed by healthy fundamentals. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Understanding Grey Market Premium (GMP)
The Grey Market Premium (GMP) is an unofficial indicator of how an IPO's shares are trading in the grey market before they are officially listed on a stock exchange. It reflects investor sentiment and demand for the IPO shares ahead of listing day.
How does it work? The grey market is an informal, over-the-counter market where investors buy and sell IPO shares before the official listing date. If an IPO has a positive GMP, it suggests that investors expect the stock to list above its issue price. A negative GMP indicates expectations of a listing below the issue price.
Example: If an IPO has an issue price of ₹100 and the GMP is ₹50, the expected listing price would be approximately ₹150 (issue price + GMP). This translates to an estimated listing gain of 50%.
Factors that influence GMP:
- Subscription levels — Higher subscription typically drives GMP up
- Market conditions — Bullish markets tend to boost GMP across all IPOs
- Company fundamentals — Strong financials and growth potential attract premium
- Industry sentiment — Positive outlook for the sector can increase demand
- IPO pricing — Reasonably priced IPOs relative to peers tend to command higher GMP
Disclaimer: GMP is an unofficial metric from the grey market and is not regulated by SEBI or any stock exchange. GMP values fluctuate frequently and should not be the sole basis for investment decisions. Always consider company fundamentals, financial health, and your own risk appetite before investing in any IPO.
Related IPO
No comments yet. Be the first to share your opinion!